10 and A Tabarin 6, 9, 10 OBJECTIVES: The corticotrophin-releasing factor (CRF)/urocortin system is expressed in the adipose tissue of mammals, but its functional role in this tissue remains unknown. METHODS: Pharmacological manipulation of the activity of CRF receptors, CRF 1 and CRF 2 , was performed in 3T3L1 white preadipocytes and T37i brown pre-adipocytes during in vitro differentiation. The expression of genes of the CRF/urocortin system and of markers of white and brown adipocytes was evaluated along with mitochondrial biogenesis and cellular oxygen consumption. Metabolic evaluation of corticosterone-deficient or supplemented Crhr1-null (Crhr1 − / − ) mice and their wild-type controls was performed along with gene expression analysis carried out in white (WAT) and brown (BAT) adipose tissues. RESULTS: Peptides of the CRF/urocortin system and their cognate receptors were expressed in both pre-adipocyte cell lines. In vitro pharmacological studies showed an inhibition of the expression of the CRF 2 pathway by the constitutive activity of the CRF 1 pathway. Pharmacological activation of CRF 2 and, to a lesser extent, inhibition of CRF 1 signaling induced molecular and functional changes indicating transdifferentiation of white pre-adipocytes and differentiation of brown pre-adipocytes. Crhr1 − / − mice showed increased expression of CRF 2 and its agonist Urocortin 2 in adipocytes that was associated to brown conversion of WAT and activation of BAT. Crhr1 − / − mice were resistant to diet-induced obesity and glucose intolerance. Restoring physiological circulating corticosterone levels abrogated molecular changes in adipocytes and the favorable phenotype of Crhr1 − / − mice. CONCLUSIONS: Our findings suggest the importance of the CRF 2 pathway in the control of adipocyte plasticity. Increased CRF 2 activity in adipocytes induces browning of WAT, differentiation of BAT and is associated with a favorable metabolic phenotype in mice lacking CRF 1 . Circulating corticosterone represses CRF 2 activity in adipocytes and may thus regulate adipocyte physiology through the modulation of the local CRF/urocortin system. Targeting CRF receptor signaling specifically in the adipose tissue may represent a novel approach to tackle obesity.
INTRODUCTION
The corticotrophin-releasing factor (CRF)/urocortin system is a complex neuroendocrine system that includes four structurally related peptides (CRF and urocortins -1, -2 and -3) and two seventransmembrane domain receptors, CRF 1 and CRF 2 , which mediate the physiological effects of these peptides. 1 CRF is a preferential CRF 1 ligand, whereas urocortin 1 has high affinity for both receptors and urocortin 2 and 3 are specific for CRF 2 . Apart from its pivotal role in orchestrating responses to stress, the CRF/urocortin system also regulates energy balance. [1] [2] [3] [4] [5] Proposed effects include modulation of energy expenditure, fuel partitioning and metabolism through various mechanisms, including the regulation of the sympathetic nervous system (SNS) activity and of glucocorticoid secretion, as well as regulation of food intake. [1] [2] [3] 5 The distinct anatomical distributions of CRF 1 and CRF 2 imply diverse physiological functions. Although the relative contribution of the two receptors in energy homeostasis remains debatable, emerging evidence suggests an independent and prominent role of the CRF 2 pathway in the CNS to regulate feeding, glucose metabolism and thermoregulation. 1,3,5,6 CRF 2 pattern of expression suggests that this receptor may also participate in the regulation of energy balance in key peripheral tissues involved in energy metabolism and modulate fuel utilization by acting locally through paracrine mechanisms at the level of pancreatic β and skeletal muscle cells. [7] [8] [9] CRF, urocortins and CRF-Rs are expressed in the white adipose tissue (WAT) of various species, including human subcutaneous and visceral white adipocytes. 1, [10] [11] [12] [13] The functional role of CRF-Rs in the adipose tissue remains unknown. Only one pharmacological study found that activation of the CRF 2 reduces lipolysis in mature human subcutaneous white adipocytes. 14 Therefore, the purpose of the present study was to investigate the functional relevance of CRF-R pathways in the adipose tissue.
MATERIALS AND METHODS
Total RNA extraction and quantitative RT-PCR (qPCR) Samples (inguinal WAT, interscapular brown adipose tissue (BAT), 3T3-L1 and T37i cells) were homogenized with lysis buffer and total RNA was extracted using Qiagen RNeasy Lipid Tissue Mini Kit (Manchester, UK), according to the manufacturer's instructions. Extracted total RNA was reverse-transcribed into cDNA by two-step reverse transcription PCR using SuperScript II Reverse Transcriptase (Invitrogen, Paisley, UK). QPCR was carried out using a Light Cycler system (Roche Molecular Biochemicals, Mannheim, Germany). The qPCR primers are listed in Supplementary  Table 1 . The reaction was carried out in a 10 μl reaction mixture containing 5 μl PCR 2 × Mastermix with 2 mM MgCl2, 0.5 μl Light Cycler DNA Master SYBRGreen I, 1 μl of each primer (2 μg μl − 1 ), and 1 μl cDNA. The qPCR protocol consisted of a denaturation step at 95°C for 15 s, following by 40 cycles of amplification at 95°C for 5 s, 58°C for 10 s, 72°C for 15 s, and finally by a melting curve analysis step at 95°C for 10 s, 56°C for 15 s and 99°C for 10 s. Quantitative amounts of gene of interest were standardized against the housekeeping genes β-actin and GAPDH. Preparations lacking RNA or reverse transcriptase were used as negative controls. RNA expression was tested in four independent experiments. Relative level of mRNA expression was calculated using the comparative (2 − ΔΔCT ) method.
3T3-L1 and T37i cell cultures
3T3-L1 cells were differentiated in growth medium (Dulbecco's modified Eagle's medium/F12 medium containing 10% bovine calf serum, 100 U ml − 1 penicillin and 100 mg ml − 1 streptomycin) and 15 nM HEPES with 1 g l − 1 glucose. Differentiation was induced by incubation with 10% fetal bovine serum with 5 μg ml − 1 insulin, 0.25 μM dexamethasone and 0.5 mM isobutyl methylxanthine for 2 days before return to growth medium. 3T3-L1 fully differentiated within 6-10 days. T37i cells were cultured in Dulbecco's modified Eagle's medium/F12 medium with 10% fetal bovine serum, 2 mM glutamine, 100 U ml − 1 penicillin and 100 mg ml − 1 streptomycin, and 15 nM HEPES with 1 g l − 1 glucose. Differentiation was achieved by incubating sub-confluent undifferentiated T37i cells with 2 nM triiodothyronine and 20 nM insulin for 8-12 days. In some experiments, 3T3L1 preadipocytes were exposed to CRF (100 nM), urocortin 2 (100 nM) and/or the CRF 1 antagonist NBI 27914 (1 μM) for various time periods (2, 4, 6 or 8 days) . At the end of the required period, cells were washed with ice-cold PBS and lysed in RNA extraction buffer. Extracted RNA was further processed by qPCR.
Immunocytochemistry
Adipose tissue samples were fixed for 16-24 h in 4% paraformaldehyde at 4°C, paraffin embedded and cut at 7 μm using a microtome (Leica Microsystems Ltd, Milton Keynes, UK). Fixed tissues were washed with filter-sterilized PBS. Non-specific banding was blocked with 3% BSA in PBS-Triton X-100 (0.01%) for 1 h.
For cell fixation, round glass cover slips (25 mm) were treated with acetic acid for 30 min, then with 70% ethanol for 30 min, and acetone containing 200 μl 3-(aminopropyl) triethoxy saline. Prior to use, the plates were sterilized by ultraviolet radiation for 30 min. The cover slips were coated with 100 μg ml − 1 poly-D-lysine in PBS. After 10 min of soaking, cover slips were washed with filter-sterilized PBS. Confluent cells were trypsinized and resuspended in 15 ml of media. A total of 100-150 μl of cells were left on a cover slip for 20 min, and 4 ml medium was added. When appropriate, media were removed from the wells, and cells were briefly washed with PBS and fixed with 0.5 ml of 4% paraformaldehyde in PBS for 30 min. After washing with PBS, cells were processed for immunostaining.
After three washes with PBS, slides were incubated overnight at 4°C with primary antibodies (1:50 and 1:100) for cytochrome c oxidase IV, (Invitrogen) or UCP1 (Abcam, Cambridge, UK). Then, slides were washed with PBS and incubated with secondary antibodies (donkey anti-rabbit Alexa-Fluor488, Invitrogen) for 1 h at room temperature. Sections were mounted with VectaShield Hard Set mounting medium. Vector Laboratories, Inc., Orton Southgate, Peterborough, UK). Samples were examined under an oil immersion objective using Leica model DMRE laser scanning confocal microscope with TCS SP2 scan head. Between 30 and 35 individual cells in six random fields of view were selected and analyzed. The scan speed was 400 Hz, and the format was 1024 × 1024 pixels. No specific fluorescence was observed in cells treated only with the secondary antibody. The images were manipulated with Leica and Image J (National Institute of Health, Bethesda, MD, USA) software.
Cellular respiration assay 3T3L1 preadipocytes were exposed to CRF (100 nM), Urocortin 2 (100 nM), isoproterenol (1 μM) and NBI 27914 (1 μM). On days 4 and 8 of cell differentiation, measurements of the oxygen concentration were made over 1-2 min using the Seahorse XF24 instrument (Seahorse Bioscience, North Billerica, MA, USA) and the rates of oxygen consumption were determined. Dimethyl sulfoxide was used as the vehicle throughout the Seahorse respiration assays. Cells were equilibrated in the medium at 37°C for 30 min, and then baseline metabolic rates were measured over the next 30 min and were reported in nM min − 1 of the oxygen consumption rate. Results were normalized to total protein level.
Animal procedures
All experiments involving animals were conducted in strict compliance with the European Union recommendations (2010/63/EU) and were approved by the French Ministry of Agriculture and Fisheries (animal experimentation authorization n°3309004).
Housing and diets. Crhr1-deficient mice (Crhr1 − / − ) on a C57BL/6Jx129Sv-Ter genetic background were generated and genotyped as previously described 15 and their wild-type (Crhr1 +/+ ) littermates used as controls. Experiments were performed in 7-8-months old individually housed male mice under a 12/12 h light/dark cycle and controlled temperature (23°C). The regular chow diet contained 9.5% Kcal as fat with an energy density of 2.9 Kcal g − 1 (AO4, UAR, Epinay sur Orge, France). The high-fat diet contained 45% Kcal as fat with an energy density of 4.73 Kcal g − 1 (N°12450B, Research Diets-Teklad, Madison, WI, USA). Food intake and body weight were recorded and feed efficiency calculated as body gain weight (g)/total caloric intake (100/Kcal). Corticosterone (Sigma-Aldrich, Saint Quentin Fallavier, France) was supplemented at 5 μg ml − 1 in drinking water while Crhr1 +/+ mice received the vehicle only (0.2% ethanol in drinking water).
Body composition. Whole-body composition was evaluated by dual energy X-ray absorptiometry (Piximus, General Electric, Belfort, France).
Locomotor activity. Locomotor activity of Crhr1 − / − and Crhr1 +/+ littermates was evaluated using individual locomotor activity cages with two levels photocell beams allowing recording of both horizontal (locomotion) and vertical (rearing) behavior (Imetronic, Pessac, France). Mice were housed for 22 h a day for 3 days for habituation and then locomotor activity was recorded.
Plasma measurements. Blood samples were collected by tail bleeding in heparinized capillary tubes. Blood samples for corticosterone measurement were obtained 1 h before the onset of the dark phase within 1 min of removal of mice from their cage. Corticosterone, leptin and insulin were measured using immunoassays (ICN Pharmaceuticals, Orsay, France and Linco, St Charles, MO, USA). Triglycerides were measured using an enzymatic kit (PAP 150 kit, bioMerieux, Craponne, France). Plasma catecholamines were measured by HPLC as previously described. 16 Whole β-hydroxybutyrate was measured using the β-hydroxybutyrate dehydrogenase method. 17 For the glucose tolerance test, mice were tested in the morning after an overnight fast. Glucose (2 g × kg − 1 in saline) was administered intraperitoneally and tail blood collected immediately before and 30, 60, 90 and 120 min after injection. Glucose was measured using a Lifescan One Touch glucometer (Johnson and Johnson, Issy-les-Moulineaux, France). Homeostasis model assessment-estimated insulin resistance was calculated using the formula [insulin (mU l − 1 ) × glucose (mg dl − 1 )]/405.
Statistics
Data are presented as mean ± s.e.m. Data were tested for homogeneity and comparison between groups was performed by Student's unpaired t-test with Prism software (GraphPad, La Jolla, CA, USA). For multiple For data with non-normal distribution, the Kruskal-Wallis analysis of variance followed by Bonferroni test was used. P o0.05 was considered significant.
RESULTS

Regulation of the adipocyte CRF/urocortin system in vitro
To determine the role of the CRF/urocortin system in adipocytes, we first investigated the expression of CRF 1 and CRF2 and the impact of their pharmacological manipulation in 3T3L1 white preadipocytes or T37i brown pre-adipocytes. 18 ,19 CRF 1 and CRF 2 as well as CRF, Urocortin 1 and Urocortin 2 mRNAs were detected in both cell lines (Figures 1a and 2a ). Treatment of 3T3L1 cells with CRF increased CRF 1 mRNA expression only (Figure 1a ). Differently, treatment with the specific CRF 2 agonist Urocortin 2 during differentiation stimulated mRNA expression of CRF and of the CRF 2 pathway components Urocortin 2 and CRF 2 (Figure 1a ). Inhibition of the endogenous CRF 1 activity by the specific CRF 1 antagonist NBI-27914 mimicked the effects of Urocortin 2, suggesting that activity of the CRF 1 pathway spontaneously represses the CRF 2 pathway. Roughly similar changes were also induced in the brown adipocyte precursors T37i cells (Figure 2a ). CRF 1 and CRF 2 pathways differently regulate the transcriptional machinery promoting the brown adipocyte phenotype in vitro During 3T3L1 cells differentiation, activation of the CRF 2 pathway by Urocortin 2 dramatically increased mRNA expression of PRDM16 and BMP7, two key factors inducing brown adipocyte phenotype and able to stimulate beige adipocyte differentiation [20] [21] [22] (Figure 1b ). Furthermore, Urocortin 2 increased the mRNA expression of PGC1-α and of UCP1, two markers of brown or beige adipocyte activation 20, 21 (Figure 1b ). Similar effects, albeit less potent, were induced by the β-receptor agonist isoproterenol, a strong activator of BAT thermogenesis that induces ectopic expression of UCP1 in WAT. 23 While simulating the expression of brown-fat-promoting genes, Urocortin 2 inhibited the differentiation-dependent induction of the white adipocyte gene markers leptin, Wdnm1, resistin and chemerin ( Figure 1b ). Conversely, exposure of 3T3L1 cells to the preferential CRF 1 agonist CRF during differentiation did not induce expression of brown-fat-promoting genes, but enhanced by 4-20fold the expression of the aforementioned white adipocyte gene markers (Figure 1b ). Blockade of CRF 1 by NBI-27914 mimicked, although less potently, the effects of Urocortin 2 (Figure 1b) . Similarly, Urocortin 2 induced the expression of molecular markers characteristic of brown adipocyte differentiation in T37i cells (Figure 2b) . Activation of the CRF 2 pathway and inhibition of the CRF 1 pathway induces functional changes consistent with the browning of white preadipocytes To further investigate the opposing actions of CRF 1 and CRF 2 pathways on the white pre-adipocyte transcriptional machinery, we studied the functional consequences of pharmacological manipulations of CRF-Rs on mitochondrial biogenesis in 3T3L1 cells. Urocortin 2 and, to a lesser extent, NBI-27914 increased protein expression of cytochrome c oxidase IV, a marker of mitochondrial biogenesis, in a time-dependent manner (Figure 1c ). To determine whether these molecular changes were associated with changes in cellular metabolism, we measured the oxygen consumption rate in stimulated 3T3L1 cells. Treatment with Urocortin 2 during differentiation enhanced oxygen consumption rate, whereas CRF had no effect (Figure 1d ). NBI-27914 mimicked to a lesser extent the effects of Urocortin 2 (Figure 1d ); Whereas the combination of these two drugs had no additive effect over Urocortin 2-induced oxygen consumption rate (data not shown). These results are therefore consistent with increased mitochondrial respiration confirming the transdifferentiation of white pre-adipocytes towards metabolically activated 'beige' adipocytes 20, 21, 24, 25 as the result of the activation of the CRF 2 pathway and, to a lesser extent, to the inhibition of the CRF 1 pathway.
These findings therefore identify divergent roles for CRF 1 and -R 2 pathways in pre-adipocyte differentiation and pinpoint the importance of the local interplay between the CRF 1 and CRF 2 pathways regulating the fate of adipocyte precursors in vitro.
Increased CRF 2 activity in Crhr1 − / − mice induces browning of WAT in vivo that is reversed by corticosterone To confirm the hypothesis that unimpeded CRF 2 activity induces brown conversion of WAT in vivo, we performed complementary studies in Crhr1 − / − and their Crhr1 +/+ littermates. Deletion of Crhr1 decreases adrenocorticotropic hormone and corticosterone secretion. 15 We therefore also studied Crhr1 −/− mice supplemented with corticosterone in drinking water.
As expected, plasma corticosterone at the time of the diurnal peak in Crhr1 −/− mice was decreased compared with that of Crhr1 +/+ mice (3.9 ± 0.5 vs 23.8 ± 3.85 ng ml − 1 , respectively, Po 0.001), whereas it was restored to physiological levels in steroid-supplemented Crhr1 −/− mice (Crhr1 −/− Cort) (27.3 ± 5.6 ng × ml − 1 ). As Crhr1 deletion induces variable alterations in the expression of other components of the CRF/urocortin system within tissues, 11, 26 we carried out gene expression analysis in the adipose tissue of Crhr1 −/− mice. Molecular changes in the inguinal WAT of Crhr1 −/− mice were similar to those induced by the pharmacological inhibition of the CRF 1 pathway in 3T3L1 cells, including a three to fourfold increase in CRF, Urocortin 2 and CRF 2 mRNA expression ( Figure 3a) . Urocortin 2 and CRF 2 protein expression was also increased (Figure 3a , right panels). Similar changes were observed in the BAT (Figure 4a ). Interestingly, mRNA levels of CRF, Urocortin 2 and CRF 2 in WAT and BAT were comparable between Crhr1 +/+ and Crhr1 −/− Cort mice, suggesting that the upregulation in Urocortin 2 and CRF 2 expression induced by the lack of CRF 1 signaling in vivo is secondary to the reduced levels of circulating corticosterone.
Similarly to our in vitro findings, genes involved in determining the beige phenotype were upregulated in the inguinal WAT of Crhr1 −/− mice, whereas the expression of WAT-specific genes was strongly decreased (Figure 3b ). These changes were associated with a dramatic increase in the expression of UCP1 and cytochrome c oxidase IV proteins, confirming the browning of WAT (Figure 3c ). Upregulation of brown adipocyte gene markers was also observed in the BAT of Crhr1 −/− mice (Figure 4b) . Importantly, β3-adrenergic receptor expression in inguinal WAT and BAT (data not shown) and plasma levels of norepinephrine (Crhr1 +/+ : 13.3 ± 1.5 μg l − 1 vs Crhr1 −/− : 14.9 ± 1.2 μg l − 1 , P = NS) did not differ between genotypes. As already reported elsewhere, 27 Crhr1 − / − mice display a lean phenotype and resistance to high-fat diet that is reversed by physiological circulating levels of corticosterone To determine the in vivo metabolic impact of the above-described changes, we further characterized Crhr1 −/− mice. Adult Crhr1 −/− mice maintained on regular chow displayed similar weight as compared with their Crhr1 +/+ littermates, but had a decrease in fat mass and an associated increase in lean mass ( Supplementary Figures 1A-D) . The reduced adiposity could not be explained by differences in food intake or locomotor activity ( Supplementary Figures 1E and F) . Crhr1 −/− mice displayed reduced fasting plasma insulin concentrations, although glucose tolerance was similar between genotypes ( Supplementary Figures 1G and H) . Crhr1 −/− mice maintained on a high-fat diet for 50 days showed reduced body weight gain, adiposity and leptin levels compared with Crhr1 +/+ mice ( Figures  5a-d) . Locomotor activity and caloric intake were similar between genotypes (Figures 5e and f) whereas Crhr1 −/− mice had decreased feed efficiency (Figure 5g ), suggesting an increase in energy dissipation. Accordingly, Crhr1 −/− mice had increased plasma hydroxybutyrate levels (Figure 6h) , characteristic of increased fatty acid oxidation. Crhr1 −/− mice were also protected from diet-induced metabolic alterations and had significantly lower fasting homeostasis model assessment index, lower plasma triglycerides and improved glucose tolerance as compared with Crhr1 +/+ mice (Figures 5h-j) . Conversely, the replacement of physiological levels of corticosterone abolished the protection against the deleterious effects of a high-fat diet (Figures 5a-k) .
DISCUSSION
This study demonstrates that, in vitro, the CRF/urocortin system critically contributes to regulate the differentiation fate and function of preadipocytes cell lines and, more specifically, that increased activity of the CRF 2 pathway, through local mechanisms, induces transdifferentiation of white pre-adipocytes to metabolically active beige adipocytes and promotes differentiation of BAT. These pharmacological results were corroborated in vivo using Crhr1 −/− mice in which CRF 2 activity is unimpeded and that show molecular evidence of browning of WAT, activation of BAT and resistance to diet-induced obesity. Our study also identifies a previously unknown role of circulating corticosterone in hampering the browning of WAT and activation of BAT through the inhibition of the CRF 2 pathway in adipocytes.
In accordance with the previously described expression of the CRF/urocortin system in the adipose tissue of humans and various animal species, 1,10-13 we demonstrate that white and brown preadipocytes cell lines express the mRNAs of CRF 1 and CRF 2 and their ligands CRF, Urocortin-1 and Urocortin-2. The increased expression of Urocortin 2 and CRF 2 mRNAs after Urocortin 2 treatment suggests that activation of the CRF 2 pathway establishes a positive feedback loop potentially favoring further auto-activation. Conversely, the increased expression of the components of the CRF 2 pathway observed after treatment with the CRF 1 antagonist NBI-27914 implies that the constitutive activity of the CRF 1 pathway limits the expression and function of the CRF 2 pathway. Although we did not measure the CRF/ urocortin family peptides in the cell culture media, the local expression of the members of the CRF system on the one hand and the results of the in vitro pharmacological studies including use a receptor antagonist on the other hand suggests a paracrine regulation of the CRF/urocortin system within the adipocytes.
Our in vitro experiments demonstrate the ability of the CRF/ urocortin system to regulate the transcriptional machinery governing the differentiation of preadipocyte cell lines. Divergent roles for CRF 1 and CRF 2 pathways were identified. Activation of CRF 2 signaling stimulated the transcriptional machinery characteristic of the differentiation and activation of brown adipocytes in both 3T3L1 and T37i cell lines, while inhibiting the induction of white adipocytes gene markers in white preadipocytes, presumably through the induction of key transcriptional factors such as BMP7 and PRDM16. 20, 21, 28 Inhibition of CRF 1 mimicked, although to a lesser extent, the consequences of the activation of the CRF 2 pathway. The transformation of white preadipocytes into activated 'beige' adipocytes suggested by the increase in PGC-1α and UCP1 mRNAs and consistent with a transdifferentiation process 24, 25, 29 was confirmed by the increased mitochondrial biogenesis and cellular respiration induced by CRF 2 activation and, to a lesser degree, CRF 1 inhibition. Altogether, these in vitro data suggest that the balance between the CRF 1 and CRF 2 intracellular signaling in pre-adipocytes play an important role in determining, through paracrine mechanisms, cell commitment towards divergent differentiation. More specifically in white preadipocyte cell lines, the CRF 2 pathway strongly stimulates the differentiation towards a brown adipocyte phenotype whereas activation of the CRF 1 pathway by endogenous CRF prevents it, allowing the expected programmed differentiation towards a white adipocyte phenotype. Notably, several studies have stressed the importance of the balance between the activity of the CRF 1 and CRF 2 pathways in the regulation of gastro-intestinal motility, behavioral responses to stressors and SNS activity. 2, 5, 26, 30 In agreement with our in vitro results, Crhr1 −/− mice exhibited features suggesting an unrestrained CRF 2 activity, including an increased expression of Urocortin 2 and CRF 2 mRNA levels in inguinal WAT and interscapular BAT. In agreement with the in vitro results observed after pharmacologically induced upregulation of CRF 2 mRNA expression or direct activation of the CRF 2 pathway, these changes were associated with an increased expression of the transcriptional machinery characteristic of brown adipocytes in both WAT and BAT and decreased expression of the white adipocytes gene markers.
The CRF 1 pathway stimulates the activity of the SNS. 1, 2, 31 Crhr1 −/− mice had similar levels of β3-adrenergic receptor expression in adipocytes and similar plasma levels of norepinephrine compared with Crhr1 +/+ mice. Thus, it is unlikely that the browning of WAT and activation of BAT observed in Crhr1 −/− mice results from a local or systemic increase in SNS activity. However, whether the changes observed in the WAT of Crhr1 −/− mice represents recruitment of beige adipocytes or transdifferentiation of white adipocytes deserves further studies.
In accordance with a functional activation of brown and beige adipocytes through heightened CRF 2 activity, Crhr1 −/− mice were obesity resistant and showed features typical of increased energy dissipation, overall suggesting an important role for the CRF 2 pathway in the regulation of energy balance in vivo. Interestingly, peripheral chronic administration of a CRF 2 agonist in rats reduces white fat mass while inducing expression of typical muscle genes in the WAT. 32 Elsewhere, transgenic expression of the CRF 2 agonist Ucn3 or in vitro stimulation of the CRF 2 pathway with Urocortin 2 activates energy dissipating substrate cycles in the muscle and upregulates UCP2 and UCP3 mRNAs. 9, 33 Taking into account that myocytes and brown adipocytes are derived from a common mesenchymal precursor, 28, 34 we might speculate for a broader role of the CRF 2 pathway in promoting mitochondrial thermogenesis in peripheral tissues, such as the adipose tissue and skeletal muscle. We therefore cannot exclude at present the involvement of additional mechanisms to the modification of adipocyte activity to account for the favorable metabolic phenotype of Crhr1 −/− mice including increased lipid oxidation in the liver. 13 As our in vitro studies involved pre-adipocyte cell lines and whole animal studies involved loss-of-function since birth, the effects of manipulation of the CRF system after differentiation of adipocytes or during adulthood remain to be determined. Complementary studies using chronic infusion of Ucn2 or selective and inducible knockdown of Crhr1 as well as inducible overexpression of Crhr2 or Ucn2 in the adipose tissue will allow addressing these important mechanistic issues.
Although the importance of glucocorticoids in the differentiation of white preadipocytes is well acknowledged, 18, 19, 35 our experiments also identify a previously unknown role of corticosterone in white adipocyte biology and energy balance.
Glucocorticoids influence the expression of components of the CRF/urocortin system in a tissue-selective manner. 11, 36, 37 Indeed, corticosterone administration inhibits the overexpression of Urocortin 2 and CRF 2 in the skin 11 and hypothalamus 36 of Crhr1 −/− and adrenalectomized mice. Accordingly, our data suggest a repression of CRF 2 activity in white adipocytes by physiological levels of corticosterone, which allow the expected white adipocyte differentiation. Conversely, corticosterone deficiency in Crhr1 −/− mice results in unrestrained CRF 2 activity that promotes the browning of WAT ( Figure 6 ). Concordantly, in vivo reduction of active glucocorticoids specifically in the adipose tissue of 11β-hydroxysteroid dehydrogenase type 2 transgenic mice promotes the expression of brown adipocyte markers in the subcutaneous WAT, decreases the expression of white adipocytes gene markers and is associated with increased thermogenesis, leading to resistance to diet-induced obesity. 38 Thus, corticosterone should be considered as one of the secreted molecules that is able to modulate the plasticity of adipose tissue and the induction of beige adipocytes. 21 Complementary studies focusing on the expression of components of the CRF/Ucn system in the adipose tissue of adrenalectomized mice clamped with various doses of corticosterone and of mice treated with molecules targeting the 11β-hydroxysteroid dehydrogenase in the adipose tissue are mandatory to further dissect the interactions between circulating corticosterone and adipocytes plasticity.
Finally, it should be mentioned that recent studies have shown the presence of functional brown and beige adipocytes in adult humans. 24, 39, 40 Stimulating the thermogenesis of adipose tissue represents a promising strategy to tackle obesity and type 2 diabetes. 20, 21, [41] [42] [43] In this perspective, our study suggests that the adipocyte CRF 2 pathway could be a specific target for the pharmacological treatment of metabolic disease. Figure 6 . Proposed model illustrating the role of the CRF/urocortin system and of circulating corticosterone in white adipocytes differentiation. CRF 1 and CRF 2 intracellular signaling in white adipocytes determines cell commitment towards divergent differentiation through autocrine mechanisms. Activation of the CRF 2 pathway by local urocortin stimulates the differentiation of white adipocytes towards a 'brown-like' phenotype, whereas activation of the CRF 1 pathway by local CRF prevents it, thus allowing the expected differentiation towards a white adipocyte phenotype. CRF 1 signaling in the central nervous system stimulates the activity of the hypothalamo-pituitary-adrenal axis and results in corticosterone secretion. Physiological levels of circulating corticosterone dampen the activation of the CRF 2 pathway in adipose tissue and repress the browning of WAT through endocrine mechanisms.
